An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2017
At a glance
- Drugs Docetaxel (Primary) ; Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Jun 2017 Planned End Date changed from 2 Jan 2018 to 29 Jun 2018.
- 12 Jun 2017 Planned primary completion date changed from 2 Jan 2018 to 29 Jun 2018.
- 22 Aug 2016 Status changed from active, no longer recruiting to recruiting.